The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 3 , Pages 732-740 , March 2010

The novel synthetic serine protease inhibitor CU-2010 dose-dependently reduces postoperative blood loss and improves postischemic recovery after cardiac surgery in a canine model

Read at the Eighty-ninth Annual Meeting of The American Association for Thoracic Surgery, Boston, Massachusetts, May 9–13, 2009.

  • Gábor Szabó, MD, PhD

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    • Corresponding Author InformationAddress for reprints: Gábor Szabó, MD, PhD, Department of Cardiac Surgery, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
    • ,
  • Gábor Veres, MD

      Affiliations

    • Department of Cardiovascular Surgery, Semmelweis University Medical School, Budapest, Hungary
    • ,
  • Tamás Radovits, MD

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    • ,
  • Humaira Haider

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    • ,
  • Nelli Krieger

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    • ,
  • Susanne Bährle, MD

      Affiliations

    • Department of Cardiology, Angiology and Pulmonology, University of Heidelberg, Heidelberg, Germany
    • ,
  • Silke Niklisch

      Affiliations

    • The Medicine Company, München, Germany
    • ,
  • Christiane Miesel-Gröschel

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany
    • ,
  • Andreas van de Locht, PhD

      Affiliations

    • The Medicine Company, München, Germany
    • ,
  • Matthias Karck, MD

      Affiliations

    • Department of Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

Received 4 May 2009 ,Revised 4 October 2009 ,Accepted 31 October 2009.

References 

  1. Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83:S27–S86
  2. Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood. 1993;82:3350–3357
  3. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356:2301–2311
  4. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation. 2007;115:2801–2813
  5. Henry DA, Carless P, Moxey A, O'Connell D, Stokes B, McClelland B, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007;CD001886
  6. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg. 2004;128:442–448
  7. Zufferey P, Merquiol F, Laporte S, Decousus H, Mismetti P, Auboyer C, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery?. Anesthesiology. 2006;105:1034–1046
  8. Harmon D, Lan W, Shorten G. The effect of aprotinin on hypoxia-reoxygenation–induced changes in neutrophil and endothelial function. Eur J Anaesthesiol. 2004;21:973–979
  9. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. The BI: a comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–2331
  10. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358:784–793
  11. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006;354:353–365
  12. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A, et al. A propensity score case–control comparison of aprotinin and tranexamic acid in high-transfusion–risk cardiac surgery. Transfusion. 2006;46:327–338
  13. Mouton R, Finch D, Davies I, Binks A, Zacharowski K. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study. Lancet. 2008;371:475–482
  14. Westaby S. Aprotinin: twenty-five years of claim and counterclaim. J Thorac Cardiovasc Surg. 2008;135:487–491
  15. Dietrich W, Busley R, Boulesteix AL. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology. 2008;108:189–198
  16. Edmunds LH, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82:2315–2322
  17. Katz BA, Sprengeler PA, Luong C, Verner E, Elrod K, Kirtley M, et al. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem Biol. 2001;8:1107–1121
  18. Szabó G, Veres G, Radovits T, Haider H, Krieger.N, Bährle S, et-al. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular function after cardiac surgery. J Thorac Cardiovasc Surg. In press
  19. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg. 2003;96:51–57
  20. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1991;101:958–967
  21. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet. 1987;2:1289–1291
  22. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg. 1994;107:554–561
  23. Bittner HB, Lamke J, Lange M, Rastan A, Mohr FW. The impact of aprotinin on blood loss and blood transfusion in off pump coronary artery bypass grafting. Ann Thorac Surg. 2008;85:1662–1668
  24. Byun Y, Chang LC, Lee LM, Han IS, Sinh VK, Yang VC. Low molecular weight protamine: a potent but nontoxic antagonist to heparin/low weight heparin. ASAIO J. 2000;46:435–439
  25. Dietrich W, Nicklisch S, Koster A, Spannagl M, Giersiefen H, van de Locht A. CU-2010—a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties. Anesthesiology. 2009;110:123–130
  26. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;5:886–888
  27. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth. 2004;92:178–186
  28. McCarthy RJ, Tuman KJ, O'Connor C, Ivankovich AD. Aprotinin pretreatment diminishes postischemic myocardial contractile dysfunction in dogs. Anesth Analg. 1999;89:1096–1100
  29. McEvoy MD, Sabbagh MJ, Taylor AG, Zavadzkas JA, Koval CN, Stroud RE, et al. Aprotinin modifies left ventricular contractility and cytokine release after ischemia–reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009;108:399–406
  30. Buerke M, Pruefer D, Sankat D, Carter JM, Buerke U, Russ M, et al. Effects of aprotinin on gene expression and protein synthesis after ischemia and reperfusion in rats. Circulation. 2007;116(11 Suppl):I121–I126
  31. Carter JM, Buerke U, Rössner E, Russ M, Schubert S, Schmidt H, et al. Anti-inflammatory actions of aprotinin provide dose-dependent cardioprotection from reperfusion injury. Br J Pharmacol. 2008;155:93–102
  32. Khan TA, Bianchi C, Voisine O, Feng J, Baker J, Hart M, et al. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg. 2004;128:602–608
  33. Khan TA, Bianchi C, Araujo E, Voisine P, Xu SH, Feng J, et al. Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. Circulation. 2005;112(9 Suppl):I196–I201
  34. Wendel HP, Heller W, Michel J, Mayer G, Ochsenfahrt C, Graeter U, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg. 1995;109:1164–1172
  35. Royston D, Levy JH, Fitch J, Dietrich W, Body SC, Murkin JM, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg. 2006;103:1082–1088

 Disclosures: Andreas van de Locht is an employce of Curacyte, GmbH; Gábor Szabó reports fees and grant support from Curacyte.

PII: S0022-5223(09)01555-4

doi: 10.1016/j.jtcvs.2009.10.059

The Journal of Thoracic and Cardiovascular Surgery
Volume 139, Issue 3 , Pages 732-740 , March 2010

Article Tools

* Image Usage & Resolution